Supplementary Table S1 from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol

<p>Gene sets examined.</p>

Na minha lista:

Detalhes bibliográficos
Autor principal:	Karlijn Verkerk (20366560) (author)
Outros Autores:	Soemeya F. Haj Mohammad (22752250) (author), Laurien J. Zeverijn (19529062) (author), Birgit S. Geurts (19529065) (author), Ilse A.C. Spiekman (20366566) (author), Florentine A.J. Verbeek (22752253) (author), Hans Timmer (22752256) (author), Maud A. van Maren (22752259) (author), V. van der Noort (22752262) (author), Miguel Parra-Martinez (22752265) (author), Paul Roepman (19529620) (author), Anne M.L. Jansen (15034226) (author), Wendy W.J. de Leng (19529623) (author), Serena Marchetti (22752268) (author), Kim Monkhorst (9620819) (author), Henk M.W. Verheul (15034232) (author), Hans Gelderblom (9358447) (author), Emile E. Voest (18281140) (author)
Publicado em:	2025
Assuntos:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Immunotherapy Biomarkers for immunotherapy Checkpoint blockade Combination immunotherapy Precision Medicine
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados